S
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Stacie M. Jones is a Professor at the University of Arkansas for Medical Sciences, with a research focus on food allergies and immunotherapies. Her work investigates novel treatments and diagnostic approaches for conditions such as peanut allergy and multiple food allergies. She has led studies evaluating the efficacy and safety of treatments like Omalizumab and epicutaneous immunotherapy in various age groups, including toddlers and children.
Her research group has contributed to updating grading scales for allergic reactions and exploring the role of allergen-specific T cells in immunotherapy outcomes. Jones's scholarship metrics include an h-index of 68, over 439 publications, and more than 21,000 citations, designating her as a highly cited researcher. She actively collaborates with researchers at the University of Arkansas for Medical Sciences, including Amy M. Scurlock, Robbie Pesek, Brandi Whitaker, and Emily Seminara, with whom she shares numerous publications.
Metrics
- h-index: 68
- Publications: 439
- Citations: 21,261
Selected Publications
-
Implementation of early peanut introduction among providers in a southern US state (2026)
-
Dupilumab Failures in Pediatric and Adolescent Eosinophilic Esophagitis: A Retrospective Cohort Study (2026)
-
Management of Gastrointestinal Symptoms During Oral Immunotherapy: Guidance from OUtMATCH Investigators (2026)
-
Genetic Determinants of Peanut‐Specific <scp>IgG4</scp> Levels in the Context of Sustained Oral Peanut Exposure in the <scp>LEAP</scp> Study (2026)
-
Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies (2025)
-
Introduction of allergenic foods after treatment with omalizumab (2025)
-
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE (2025)
-
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy (2024)
-
Omalizumab Implementation in Practice: Lessons Learned From the OUtMATCH Study (2024)
-
Impact of Atopic Status on Clinical Presentation and Treatment Response in Pediatric Patients With Eosinophilic Esophagitis (2024)
-
Enhanced Gut Microbiome Capacity for Amino Acid Metabolism is associated with Peanut Oral Immunotherapy Failure (2024)
-
Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow’s Milk Allergy (2024)
-
Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial (2024)
-
Food insecurity and allergic diseases: A call to collective action (2023)
-
Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age (2023)
Collaboration Network
Top Collaborators
Scott H. Sicherer
Icahn School of Medicine at Mount Sinai (US)
21 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Mapping Sequential IgE-Binding Epitopes on Major and Minor Egg Allergens
Showing 5 of 21 shared publications
Robert A. Wood
Johns Hopkins University (US)
18 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Mapping Sequential IgE-Binding Epitopes on Major and Minor Egg Allergens
Showing 5 of 18 shared publications
Brian P. Vickery
Children's Healthcare of Atlanta (US)
17 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Open‐label follow‐on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age
- Food Allergen Immunotherapy in Preschool Children: Do We Have the Evidence?
Showing 5 of 17 shared publications
Wayne G. Shreffler
ENT and Allergy (US)
17 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Food-specific immunoglobulin A does not correlate with natural tolerance to peanut or egg allergens
- Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
Showing 5 of 17 shared publications
Edwin Kim
University of North Carolina at Chapel Hill (US)
16 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
- Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
Showing 5 of 16 shared publications
A. Wesley Burks
University of North Carolina at Chapel Hill (US)
14 shared publications
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Mapping Sequential IgE-Binding Epitopes on Major and Minor Egg Allergens
- Food-specific immunoglobulin A does not correlate with natural tolerance to peanut or egg allergens
- Allergen recognition by specific effector Th2 cells enables <scp>IL</scp> ‐2‐dependent activation of regulatory T‐cell responses in humans
- Longitudinal dynamics of the gut microbiome and metabolome in peanut allergy development
Showing 5 of 14 shared publications
Donald Y.M. Leung
National Jewish Health (US)
14 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Mapping Sequential IgE-Binding Epitopes on Major and Minor Egg Allergens
- Food-specific immunoglobulin A does not correlate with natural tolerance to peanut or egg allergens
Showing 5 of 14 shared publications
Hugh A. Sampson
12 shared publications
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Mapping Sequential IgE-Binding Epitopes on Major and Minor Egg Allergens
- Food-specific immunoglobulin A does not correlate with natural tolerance to peanut or egg allergens
- Allergen recognition by specific effector Th2 cells enables <scp>IL</scp> ‐2‐dependent activation of regulatory T‐cell responses in humans
- Longitudinal dynamics of the gut microbiome and metabolome in peanut allergy development
Showing 5 of 12 shared publications
George Du Toit
Guy's and St Thomas' NHS Foundation Trust (GB)
11 shared publications
- Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
- Open‐label follow‐on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy
- Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age
- Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials
- Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE
Showing 5 of 11 shared publications
Sayantani Sindher
Stanford University (US)
11 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
- Food-specific immunoglobulin A does not correlate with natural tolerance to peanut or egg allergens
- Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
- Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow’s Milk Allergy
Showing 5 of 11 shared publications
R. Sharon Chinthrajah
Palo Alto University (US)
10 shared publications
- Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Food-specific immunoglobulin A does not correlate with natural tolerance to peanut or egg allergens
- Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
- HLA-associated outcomes in peanut oral immunotherapy trials identify mechanistic and clinical determinants of therapeutic success
Showing 5 of 10 shared publications
Julie Wang
Icahn School of Medicine at Mount Sinai (US)
10 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
- Allergen recognition by specific effector Th2 cells enables <scp>IL</scp> ‐2‐dependent activation of regulatory T‐cell responses in humans
- Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
- Allergen recognition by specific effector Th2 cells enables IL-2-dependent activation of regulatory T cell responses in humans
Showing 5 of 10 shared publications
Amy M. Scurlock
Arkansas Children's Hospital
9 shared publications
In database
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Food insecurity and allergic diseases: A call to collective action
- Introduction of allergenic foods after treatment with omalizumab
- Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi-Allergen OIT
- Assessment of Anxiety, Depression and Resilience in Food-Allergic Adolescents and Primary Caregivers During the COVID-19 Pandemic
Showing 5 of 9 shared publications
Jonathan M. Spergel
Children's Hospital of Philadelphia (US)
9 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
- Omalizumab for the Treatment of Multiple Food Allergy (OUtMATCH)
- Introduction of allergenic foods after treatment with omalizumab
Showing 5 of 9 shared publications
J. Andrew Bird
The University of Texas Southwestern Medical Center (US)
8 shared publications
- Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)
- Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow’s Milk Allergy
- Omalizumab Implementation in Practice: Lessons Learned From the OUtMATCH Study
- Safety of Peanut (Arachis Hypogaea) Allergen Powder-dnfp in Children and Teenagers With Peanut Allergy: Pooled Analysis From Controlled and Open-Label Phase 3 Trials
- A Multicenter Assessment of Food Allergy Quality of Life in Adolescents and Caregivers in Relation to Anxiety and Depression during the COVID-19 Pandemic
Showing 5 of 8 shared publications
Similar Researchers
Based on overlapping research topics
Saumya V Joshi
University of Arkansas for Medical Sciences
Child and Adolescent Health
Immune Response and Inflammation
Disease Mechanisms Research
SYEDA SAMAR SOHAIL
University of Arkansas for Medical Sciences
Child and Adolescent Health
Immune Response and Inflammation
Disease Mechanisms Research
Robert D. Pesek
University of Arkansas for Medical Sciences
Food Allergy and Anaphylaxis Research
Child and Adolescent Health
Immune Response and Inflammation
M. L. Baldwin
University of Arkansas – Fort Smith
Immune Response and Inflammation
Disease Mechanisms Research
Health and Medical Research Impacts
Samira Z. Chandra
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Disease Mechanisms Research
Health and Medical Research Impacts
Travis Ayers
University of Arkansas for Medical Sciences
Child and Adolescent Health
Immune Response and Inflammation
Disease Mechanisms Research